Open Orphan Plc (GB:HVO) has released an update.
Open Orphan Plc, a leading contract research organization specializing in infectious and respiratory disease trials, has announced its plan to delist from Euronext Growth in order to centralize its trading on the AIM Market of the London Stock Exchange. This strategic move aims to reduce the complexities and costs associated with dual listing and will not affect the company’s trading on AIM, where its shares will continue to be available under the ticker ‘HVO’. The delisting is expected to take effect from 7.00 a.m. on 2 September 2024 following a mandatory notice period as per Euronext Growth Rules.
For further insights into GB:HVO stock, check out TipRanks’ Stock Analysis page.
